Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RX… Read more
Tectonic Therapeutic, Inc. (TECX) - Net Assets
Latest net assets as of December 2025: $251.33 Million USD
Based on the latest financial reports, Tectonic Therapeutic, Inc. (TECX) has net assets worth $251.33 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($261.04 Million) and total liabilities ($9.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $251.33 Million |
| % of Total Assets | 96.28% |
| Annual Growth Rate | 56.67% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1314.5 |
Tectonic Therapeutic, Inc. - Net Assets Trend (2016–2025)
This chart illustrates how Tectonic Therapeutic, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tectonic Therapeutic, Inc. (2016–2025)
The table below shows the annual net assets of Tectonic Therapeutic, Inc. from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $251.33 Million | +78.53% |
| 2024-12-31 | $140.78 Million | +266.33% |
| 2023-12-31 | $-84.64 Million | -85.39% |
| 2022-12-31 | $-45.65 Million | -205.17% |
| 2021-12-31 | $-14.96 Million | -105.88% |
| 2020-12-31 | $254.34 Million | +36.73% |
| 2019-12-31 | $186.01 Million | +52.24% |
| 2018-12-31 | $122.18 Million | +3531.03% |
| 2017-12-31 | $3.37 Million | -23.89% |
| 2016-12-31 | $4.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tectonic Therapeutic, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21791000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $-96.00K | -0.04% |
| Other Components | $474.16 Million | 188.66% |
| Total Equity | $251.33 Million | 100.00% |
Tectonic Therapeutic, Inc. Competitors by Market Cap
The table below lists competitors of Tectonic Therapeutic, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ioneer Ltd American Depositary Shares
NASDAQ:IONR
|
$346.45 Million |
|
Pentamaster Corporation Bhd
KLSE:7160
|
$346.47 Million |
|
Shenke Slide Bearing Corp
SHE:002633
|
$346.52 Million |
|
Guizhou Gas Group Corporation Ltd Class A
SHG:600903
|
$346.65 Million |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
$346.21 Million |
|
MEMBERSH.COLL.GR.A DL-01
F:75Z
|
$346.15 Million |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
$346.13 Million |
|
Beijing Shengtong Printing Co Ltd
SHE:002599
|
$346.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tectonic Therapeutic, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 140,776,000 to 251,329,000, a change of 110,553,000 (78.5%).
- Net loss of 74,151,000 reduced equity.
- New share issuances of 173,098,000 increased equity.
- Other comprehensive income decreased equity by 105,000.
- Other factors increased equity by 11,711,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.15 Million | -29.5% |
| Share Issuances | $173.10 Million | +68.87% |
| Other Comprehensive Income | $-105.00K | -0.04% |
| Other Changes | $11.71 Million | +4.66% |
| Total Change | $- | 78.53% |
Book Value vs Market Value Analysis
This analysis compares Tectonic Therapeutic, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.20x to 2.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $2.22 | $31.48 | x |
| 2017-12-31 | $1.69 | $31.48 | x |
| 2018-12-31 | $61.68 | $31.48 | x |
| 2019-12-31 | $81.37 | $31.48 | x |
| 2020-12-31 | $84.30 | $31.48 | x |
| 2021-12-31 | $-4.19 | $31.48 | x |
| 2022-12-31 | $-12.53 | $31.48 | x |
| 2023-12-31 | $-22.79 | $31.48 | x |
| 2024-12-31 | $9.53 | $31.48 | x |
| 2025-12-31 | $13.72 | $31.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tectonic Therapeutic, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-29.50%) is above the historical average (-85.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -105.50% | 0.00% | 0.00x | 1.22x | $-5.11 Million |
| 2017 | -554.18% | 0.00% | 0.00x | 2.09x | $-18.98 Million |
| 2018 | -37.94% | 0.00% | 0.00x | 1.09x | $-58.58 Million |
| 2019 | -39.23% | 0.00% | 0.00x | 1.08x | $-91.57 Million |
| 2020 | -47.07% | 0.00% | 0.00x | 1.07x | $-145.15 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.43 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-27.61 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-34.36 Million |
| 2024 | -41.19% | 0.00% | 0.00x | 1.09x | $-72.06 Million |
| 2025 | -29.50% | 0.00% | 0.00x | 1.04x | $-99.28 Million |
Industry Comparison
This section compares Tectonic Therapeutic, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $251.33 Million | -105.50% | 0.04x | $346.28 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |